home

BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors

TrendBIND2015-11-19 15:55 Read   317

Dosing begins in phase 1 study of Aurora B kinase inhibitor nanomedicine developed in collaboration with AstraZeneca .BIND earns $4.0 million clinical milestone

Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

TrendPfizer2015-11-19 11:26 Read   674

Breakthrough Therapy designation highlights the potential of avelumab* as a new immunotherapy for patients with metastatic Merkel cell carcinoma (MCC).Metastatic MCC is a devastating disease and if approved, avelumab could potentially become the first immunotherapy to treat metastatic MCC.

Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD

TrendBristol-Myers Squibb2015-11-17 14:08 Read   448

Daclatasvir+sofosbuvir+ribavirin regimen for 12 or 16 weeks achieved SVR12 rates of 88% and 92%, respectively, in genotype 3 patients with advanced fibrosis or cirrhosis

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

TrendArrowhead Research Corp2015-11-16 17:18 Read   762

Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLD Liver Meeting 2015 in an oral presentation and a poster showing that ARC-520, its drug candidate against chronic hepatitis B infection (HBV), leads to robust, sustained anti-viral effects in chimpanzees with chronic HBV.

GSK Announces Positive Results From Phase III BLISS-SC Study of Benlysta(R) (Belimumab) Administered Subcutaneously In Patients With Systemic Lupus Erythematosus (SLE)

TrendGSK,Belimumab,SLE2015-11-12 14:23 Read   1233

GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These results, which are being presented at the American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting, showed that Benlysta® (belimumab) 200mg administered weekly via subcutaneous injection plus standard of care (SoC), showed significantly greater reductions in disease activity compared to placebo plus SoC.

Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

TrendAmgen2015-11-11 13:44 Read   463

Amgen today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar candidate ABP 501 with adalimumab in patients with moderate-to-severe rheumatoid arthritis.

Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia

TrendTeva2015-11-10 14:11 Read   404

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to SD-809 (deutetrabenazine) for the treatment of patients with moderate to severe tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the United States

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

TrendLilly and Incyte2015-11-09 15:28 Read   1066

Improvements compared to methotrexate were seen for baricitinib alone or in combination with methotrexate as early as week 1 for all components of the ACR response (swollen and tender joint counts, pain, patient and physician global assessment of disease activity and physical function). These improvements were maintained at weeks 24 and 52

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

TrendSamsung Bioepis2015-11-09 09:54 Read   829

Positive one-year results show SB4 etanercept and SB2 infliximab investigational biosimilar candidates sustained comparable safety profiles observed in previously announced primary results

Allergan Outlines Open Science Model And Highlights Key Development Programs At R&D Day

TrendAllergan2015-11-06 16:33 Read   280

Open Science Strategy Seeks to Deliver Innovation from Healthcare Ecosystem . Company's Pipeline Features More Than 70 Mid-to-Late Stage Development Programs with Game-Changing Opportunities Across Seven Therapeutic Categories .Clinical Data and Regulatory Milestone Updates Featured in R&D Day .Allergan Builds on Open Science Strategy with Acquisition of Earfold, and Licensing of Mimetogen's Tavilermide.

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

TrendZoetis2015-11-04 10:34 Read   352

Zoetis announced an agreement to purchase PHARMAQ, the global leader in vaccines and innovation for health products in aquaculture, for a price of $765 million on a debt-free basis. Acquiring PHARMAQ strengthens Zoetis' core livestock business, giving the company a market-leading presence in the fastest growing segment of the animal health industry.

Shire is paying $5.9B for Dyax in a defensive rare disease deal

Trendstatement2015-11-03 17:39 Read   223

Shire ($SHPG) signed a deal to buy Dyax ($DYAX) for $5.9 billion, planning to snatch up a smaller competitor and fortify its rare disease business without taking its eyes off of acquisition target Baxalta ($BXLT).